Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday

Entrada Therapeutics (NASDAQ:TRDA) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect Entrada Therapeutics to post earnings of ($0.68) per share and revenue of $12.92 million for the quarter.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $12.25 million for the quarter, compared to the consensus estimate of $11.95 million. On average, analysts expect Entrada Therapeutics to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Entrada Therapeutics Stock Performance

Entrada Therapeutics stock opened at $10.99 on Wednesday. Entrada Therapeutics has a fifty-two week low of $10.80 and a fifty-two week high of $21.79. The company has a market capitalization of $411.25 million, a PE ratio of 6.91 and a beta of -0.17. The company has a 50 day moving average price of $14.06 and a 200-day moving average price of $16.18.

Insider Activity

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total transaction of $476,359.95. Following the transaction, the insider now owns 4,402,849 shares in the company, valued at $91,447,173.73. This represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 7.59% of the company’s stock.

Analyst Ratings Changes

TRDA has been the topic of several recent research reports. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm initiated coverage on Entrada Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $29.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Tuesday, February 25th. Finally, Oppenheimer raised their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.